Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.

@article{Wheeler1993PrognosticFF,
  title={Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.},
  author={Clara A. Wheeler and Myla Strawderman and Lois J. Ayash and Winthrop Hallowell Churchill and Barbara E Bierer and Anthony Elias and Dwight Gary Gilliland and Karen A Antman and Eva C. Guinan and Joseph Paul Eder},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1993},
  volume={11 6},
  pages={1085-91}
}
PURPOSE We examined a consecutive series of 78 patients with non-Hodgkin's lymphoma treated on prospective protocols with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) plus autotransplantation to determine prognostic factors for time to treatment failure. PATIENTS AND METHODS Patients with relapsed, refractory, or poor-risk intermediate- and high-grade non-Hodgkin's lymphoma were treated with CBV with autologous marrow or peripheral-blood progenitor cell support. Patient… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Molecular Genetics and Therapy of Leukemia

Cancer Treatment and Research • 1996
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…